1ba54adc-765f-403a-8987-61f94db2a65b
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 53
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- WNT_BETA_CATENIN_SIGNALING+0.230
- NOTCH_SIGNALING+0.220
- MYC_TARGETS_V1+0.130
- PEROXISOME+0.130
- E2F_TARGETS+0.110
- HEME_METABOLISM+0.110
- INTERFERON_ALPHA_RESPONSE+0.110
- FATTY_ACID_METABOLISM+0.100
- MYC_TARGETS_V2+0.080
- DNA_REPAIR+0.070
Top 10 suppressed
- MTORC1_SIGNALING-0.280
- HYPOXIA-0.270
- TNFA_SIGNALING_VIA_NFKB-0.250
- UNFOLDED_PROTEIN_RESPONSE-0.220
- KRAS_SIGNALING_UP-0.210
- MYOGENESIS-0.210
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.190
- COMPLEMENT-0.180
- INTERFERON_GAMMA_RESPONSE-0.170
- CHOLESTEROL_HOMEOSTASIS-0.160
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-78-7158-01A-11R-2039-07 | — | cohortA1 | 0.710 |
| 2 | BS_2A5R9MEJ | high-grade glioma | — | 0.696 |
| 3 | 88a33f23-72a0-439b-afc7-2623c58eb1ab | — | — | 0.679 |
| 4 | BS_N5DVEJXT | Supratentorial Ependymoma | — | 0.678 |
| 5 | MNG198 | — | — | 0.678 |
| 6 | R90 | — | — | 0.676 |
| 7 | 82958 | EPN | Supratentorial EPN | 0.675 |
| 8 | BS_EMYET8F4 | Ependymoma NOS | — | 0.671 |
| 9 | BS_N5DVEJXT | EPN | Supratentorial EPN | 0.671 |
| 10 | 425dc52d-fb29-45d5-8d94-aab524136a83 | — | — | 0.667 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 15 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| WNT_BETA_CATENIN_SIGNALING | 0.230 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.220 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.130 | Inavolisib | — uncovered |
| PEROXISOME | 0.130 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.110 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.110 | Temsirolimus | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.110 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.080 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.070 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.050 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.040 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.040 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.030 | Inavolisib | — uncovered |
| APOPTOSIS | 0.020 | Idelalisib | — uncovered |